Evaluation of the Minimum Effective Concentration of Bupivacaine (EC50) in Femoral Block for Analgesia by Ultrasound After Knee Surgery

Sponsor
Ed Carlos Rey Moura (Other)
Overall Status
Completed
CT.gov ID
NCT02124005
Collaborator
(none)
45
1
1
26
1.7

Study Details

Study Description

Brief Summary

The purpose of the study is to determine the minimum effective concentration of bupivacaine (EC50) in femoral block for analgesia by ultrasound after knee surgery.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

45 patients classified as ASA P1 or P2 aged between 18 and 65 candidates for elective knee operation via arthroscopy were included in the study. All patients received femoral nerve block guided by ultrasound with bupivacaine, 22 ml. The first patient at a concentration of 0.25%. The other patients with higher or lower concentrations if the first patient has pain> 3 or <3 on visual analogic scale respectively after awakening of surgical anesthesia. For surgical anesthesia each patient will undergo general anesthesia. At the end of the surgical procedure and anesthetic awakening patients will be evaluated for analgesia by verbal numeric scale. The modified Dixon method was used to find the EC50 and EC95 of bupivacaine for analgesia of femoral nerve block guided by ultrasound. Concentration still correlated with motor block and side effects.

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Minimum Effective Concentration of Bupivacaine (EC50) in Femoral Block for Analgesia by Ultrasound After Knee Surgery
Actual Study Start Date :
Jul 1, 2013
Actual Primary Completion Date :
Jul 1, 2015
Actual Study Completion Date :
Sep 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Femoral block, ultrasound, bupivacaine

Drug: Bupivacaine

Outcome Measures

Primary Outcome Measures

  1. Pain Scores on the Visual Analog Scale [two years]

    45 patients classified as ASA P1 or P2 aged between 18 and 65 candidates for elective knee operation via arthroscopy were included in the study. All patients received femoral nerve block guided by ultrasound with bupivacaine, 22 ml. The first patient at a concentration of 0.25%. The other patients with higher or lower concentrations if the first patient has pain> 3 or <3 on visual analogic scale respectively after awakening of surgical anesthesia. For surgical anesthesia each patient will undergo general anesthesia. At the end of the surgical procedure and anesthetic awakening patients will be evaluated for analgesia by verbal numeric scale. The modified Dixon method was used to find the EC50 and EC95 of bupivacaine for analgesia of femoral nerve block guided by ultrasound. Concentration still correlated with motor block and side effects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • patients to undergo knee surgery
Exclusion Criteria:
  • patients with coagulopathy

  • pregnant

  • infection at the puncture site

  • chronic pain

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universidade Federal de São Paulo São Paulo SP Brazil 04023-061

Sponsors and Collaborators

  • Ed Carlos Rey Moura

Investigators

  • Principal Investigator: Ed Carlos Moura, research, Federal University of São Paulo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ed Carlos Rey Moura, doctor, Federal University of São Paulo
ClinicalTrials.gov Identifier:
NCT02124005
Other Study ID Numbers:
  • EC50 femoral block bupivacaine
First Posted:
Apr 28, 2014
Last Update Posted:
Aug 1, 2017
Last Verified:
Jul 1, 2017
Keywords provided by Ed Carlos Rey Moura, doctor, Federal University of São Paulo
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2017